When to Hire a Medical Device Consulting Firm (And When It's Already Too Late)

There's a version of this conversation that goes well, and a version that doesn't. The version that doesn't usually starts the same way: a manufacturer contacts a consulting firm after they've already received an FDA deficiency, failed an audit, or discovered that the device they've spent two years developing is built around a material that's going to be difficult — or impossible — to test adequately.

None of that is unfixable. But all of it is more expensive, and more time-consuming, than it needed to be.

Here's an honest look at when bringing in a medical device consulting firm is the right call and what it costs when that decision comes too late.

The Work That Happens Before Anyone Orders a Test

A lot of manufacturers think of biocompatibility as a testing problem. Run the tests, get the results, include them in the submission. The standard says otherwise.

Under ISO 10993-1:2025, the current standard for biological evaluation of medical devices, testing is the last resort, not the starting point. The process begins with a biological evaluation plan: a documented analysis of the device's materials, manufacturing processes, intended use, body contact type, exposure duration, and patient population. From that foundation, biological hazards are identified, risks are estimated using existing data, and gaps are determined. Testing is only warranted when the available data can't adequately address a specific biological risk.

This front-end planning work is where consulting expertise pays the biggest dividends. The biological evaluation plan shapes everything that follows — which studies get commissioned, which data gets generated, and how the entire biocompatibility package is structured for submission. Get it wrong here and you're fixing it downstream.

The Stages Where Timing Actually Matters

Early Design and Material Selection

The cheapest time to involve a consulting firm is during design, specifically when materials are being selected or finalized. At this stage, a toxicologist can flag materials with known extractables concerns, identify processing residuals that will complicate chemical characterization, or catch combinations of materials that create downstream testing problems.

A material change that happens before design lock costs nothing. The same change after a clearance has been granted requires a change evaluation under ISO 10993-1:2025, potentially a new biological evaluation report, and may trigger a new 510(k) or a substantial equivalence argument that the original submission didn't anticipate.

Before Testing Is Commissioned

If material selection is already final but no testing has been ordered yet, you're still in a good position. This is the stage where a consulting firm structures the biological evaluation plan, determines what chemical characterization is actually needed, and decides which biological endpoints require testing versus which can be addressed through existing data or literature.

Manufacturers who skip this step and go straight to ordering a testing panel — either based on what a lab recommends or what they think FDA wants to see — frequently end up with studies that don't match their device's actual contact scenario, thresholds that weren't correctly applied, or a testing dataset that generates questions rather than answers.

After the Submission Is Built but Before Filing

A pre-submission review by a consulting firm can catch problems before FDA does. That's worth something. Deficiencies that could have been anticipated — gaps in the toxicological risk assessment, chemical characterization data that doesn't support the conclusions drawn, biological testing that doesn't align with the biological evaluation plan — are addressable before filing. After filing, they become deficiency letters.

After a Deficiency Letter

This is the most common entry point for consulting help, and it's the most expensive one. By the time a deficiency letter arrives, the submission has been built, filed, and reviewed. FDA has found something it can't accept. Now the work is responding to those specific questions in a way that closes them without opening new ones.

Deficiency response is a skill. The goal isn't to answer what FDA asked — it's to answer it in a way that completes the review. Responses that are technically accurate but don't address the underlying concern, or that answer one question while flagging something else, extend the review cycle. A firm that's experienced with FDA's review process on the biocompatibility side knows how to write those responses.

Responding to a deficiency is recoverable. It's just slower and more expensive than building the submission to avoid it.

After a Failed Audit or Quality System Finding

If a biocompatibility or biological evaluation process issue surfaced during an audit — whether FDA inspection or a notified body audit — a consulting firm can help remediate the documentation gaps, restructure the biological evaluation process for QMSR compliance, and prepare the corrective action response. This is a different kind of problem than a submission deficiency, but the core issue is usually the same: the biological evaluation process wasn't documented, wasn't justified, or wasn't aligned with current standards from the start.

When Is It Actually Too Late?

Genuinely too late is rare, but it does happen. The clearest examples:

The device is already on the market and a materials issue surfaces post-clearance. If a component that wasn't fully characterized turns out to have an extractables profile that raises toxicological concerns, the correction path is significantly more complicated than any pre-clearance scenario.

The design is locked around a material that can't be adequately tested or characterized. Some materials create extractables profiles that are analytically difficult, chemically complex, or produce degradation products that don't have established toxicological thresholds. When this is discovered late — after design lock, after manufacturing setup, after testing has already been run — the options narrow fast.

The submission has accumulated multiple deficiency rounds. A single deficiency letter is routine. Multiple rounds of back-and-forth on the same issues suggest that the fundamental structure of the biocompatibility package isn't working, not just the response language.

None of these situations mean the device can't be cleared. But they're all harder, slower, and more expensive than they would have been with earlier involvement.

What Early Involvement Actually Changes

Bringing in a consulting firm at the biological evaluation planning stage — before testing is commissioned — changes what the submission looks like from the start. The biological evaluation plan is built with FDA review in mind. Chemical characterization is designed to generate data that supports the toxicological risk assessment. The TRA is structured to give FDA reviewers what they need to make a determination. The biocompatibility package integrates with the broader submission rather than being assembled separately.

That's not a theoretical difference. It's the difference between a submission that moves through review and one that generates questions.

Expert Medical Device Consulting for Biocompatibility and FDA Submissions

If you're not sure whether your current stage warrants consulting involvement, that uncertainty is usually the answer.

At JL Tox Consulting, we work with medical device manufacturers and CROs at every stage of the biocompatibility and submission process — from early design and material selection through deficiency response and audit remediation.

Our medical device consulting services include:

• Biological evaluation planning — ISO 10993-1:2025 compliant strategy built for FDA review

• Chemical characterization study design — extractables and leachables methodology, threshold analysis, and data interpretation

• Toxicological risk assessment — expert TRA documentation for 510(k), PMA, and De Novo submissions

• 510(k)/PMA/De Novo submission support — biocompatibility section development integrated with your full submission strategy

• Deficiency response — targeted responses that close FDA questions without opening new ones

• Audit remediation — biological evaluation process documentation and QMSR compliance support

With over a decade of specialized experience in medical device biocompatibility and FDA regulatory submissions, Dr. James Lyons and the JL Tox team provide the toxicological and regulatory expertise needed to move your device through clearance efficiently.

Contact JL Tox Consulting to discuss your timeline and submission needs:

Email: info@JLTox.com

Phone: (877) 899-6568